Our goal is to improve the treatment and the quality of life in patients with debilitating diseases.
We are creating novel drug substances that will take advantage of small molecules and phospholipids in the areas indicated in the diagram; the precision medicine, autoimmunity and immuno-oncology, and targeted drug delivery.
Machavert targets cancers with specific oncogenic mutations and drivers that are difficult to treat. Our lead programs are target KRAS mutant cancers that comprise 30% of all cancers and DNA damage response (DDR), a mechanism that cancer cells use to override the normal DNA replication control.
KRAS mutant cancers represents roughly 30% of all cancers that are caused by numerous different mutations within the KRAS GTPase. Machavert is developing molecules to inhibit the RAS superfamily RAL (RAS-like) GTPases that are RAS effectors and critical drivers of oncogenesis. This strategy has potential to effectively suppress multiple forms of KRAS mutant cancers that collectively are driven by multiple KRAS mutations.
Machavert is developing small molecule therapeutic inhibitors of CHK2, a DDR response effector with elevated activity in response to poly ADP ribose polymerase (PARP) inhibitors. Machavert is targeting CHK2 DDR dependent solid tumor indications as a monotherapy and in combination with PARP inhibitors.
The bioactive phospholipids developed at Machavert inhibit the CDK8 signaling pathway and activate Natural Killer (NK) cells. Through this mechanism and by altering the formulations, the bioactive phospholipid nanoparticles can suppress the immune function. Machavert is developing these newly discovered properties of phospholipids for new treatments in immuno-oncology and autoimmune diseases.
Machavert has developed a bioactive phospholipid nanoparticle drug delivery platform that that preferentially delivers payloads to solid tumors. We form liposomes of defined composition and size around 100nm in diameter that can be loaded with other therapeutics and used as vessels for drug payload delivery. Machavert’s drug delivery platform shows preferential payload delivery into tumors while circumventing organs such as liver and kidney.
– Machavert hits its preclinical proof of principle milestone that small molecule RAL GTPase inhibitors suppress KRAS mutant cancer metastasis ...
AURORA, Colo., Feb. 17, 2020 /PRNewswire/ – Machavert Pharmaceuticals, a preclinical stage pharmaceutical company focused on precision medicine cancer therapies, was featured in ...
Aurora, Colo, August 27, 2019 /PRNewswire/ – Machavert Pharmaceuticals, a preclinical stage pharmaceutical company focused on precision medicine cancer therapies, announced today that ...
Machavert is a bio-pharmaceutical company that develops novel, first-in-class therapeutics to treat cancer and autoimmune diseases. Our approach takes advantage of novel substances that inhibit cancer growth, interact with the human immune system or enhance the targeting and efficacy of other therapeutics.
Our primary goal is to improve the quality of life of patients suffering from difficult to treat cancers or autoimmune disorders. Machavert currently focuses on preclinical research and development to build a robust portfolio of drug candidates for clinical trials.
We are a group of passionate innovators with multidisciplinary expertise; focused on the challenge to create new ways to treat cancer.
Director, Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai, Los Angeles, CA
Director of the Center for Cell Signaling, University of Virginia
We have partnered with leading firms to provide us with additional expertise, guidance and resources.
